The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zöller, M.
Right arrow Articles by Christ, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zöller, M.
Right arrow Articles by Christ, O.
The Journal of Immunology, 2001, 166: 3440-3450.
Copyright © 2001 by The American Association of Immunologists

Prophylactic Tumor Vaccination: Comparison of Effector Mechanisms Initiated by Protein Versus DNA Vaccination1

Margot Zöller2,*,{dagger} and Oliver Christ*

* Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg, Germany; and {dagger} Department of Applied Genetics, University of Karlsruhe, Karlsruhe, Germany

Clinical success in tumor vaccination frequently does not reach expectation. Since vaccination protocols are quite variable, we used the murine renal cell carcinoma line RENCA transfected with the lacZ gene (RENCA-{beta}-gal) to compare the efficacy of two different vaccination strategies or their combination and to elaborate on the underlying mechanisms. BALB/c mice were vaccinated either with naked lacZ DNA or with attenuated Salmonella typhimurium transformed with lacZ DNA or with dendritic cells (DC) loaded with the {beta}-galactosidase protein or mice were vaccinated with both DNA and protein. Although all regimens led to a prolongation of survival time, oral vaccination with transfected S. typhimurium followed by i.v. transfer of protein-loaded DC provided the optimal schedule. In this setting, >50% of mice remained tumor free after challenge with 10 times the lethal tumor dose of RENCA-{beta}-gal. As explored in transfer experiments, the superior efficacy of combining DNA and protein vaccination is due to the facts that 1) optimal protection depends on both activated CD4+ and CD8+ cells and 2) CD8+ CTL are most strongly activated by vaccination with transformed Salmonella, whereas vaccination with protein-loaded DC is superior for the activation of Th. The latter induced sustained activation of CTL and recruitment of nonadaptive defense mechanisms. The data demonstrate the strength of DNA vaccination, particularly by the oral route, and provide evidence that a combined treatment with protein-loaded DC can significantly increase the therapeutic efficacy.




This article has been cited by other articles:


Home page
Cancer Res.Home page
L. Zhang, L. Gao, L. Zhao, B. Guo, K. Ji, Y. Tian, J. Wang, H. Yu, J. Hu, D. V. Kalvakolanu, et al.
Intratumoral Delivery and Suppression of Prostate Tumor Growth by Attenuated Salmonella enterica serovar typhimurium Carrying Plasmid-Based Small Interfering RNAs
Cancer Res., June 15, 2007; 67(12): 5859 - 5864.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Luhrs, W. Schmidt, R. Kutil, M. Buschle, S. N. Wagner, G. Stingl, and A. Schneeberger
Induction of Specific Immune Responses by Polycation-Based Vaccines
J. Immunol., November 1, 2002; 169(9): 5217 - 5226.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
K. Haupt, M. Roggendorf, and K. Mann
The Potential of DNA Vaccination against Tumor-Associated Antigens for Antitumor Therapy
Experimental Biology and Medicine, April 1, 2002; 227(4): 227 - 237.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.